ABL2 is altered in 0.98% of head and neck carcinoma patients [2].

ABL2 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ABL2 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ACVR1B is altered in 0.46% of head and neck carcinoma patients [2].

ACVR1B is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ACVR1B status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

AKT1 is altered in 1.13% of head and neck carcinoma patients [2].

AKT1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ALK is altered in 2.95% of head and neck carcinoma patients [2].

ALK is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ALK status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

APC is altered in 3.22% of head and neck carcinoma patients [2].

APC is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains APC status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ASXL1 is altered in 4.63% of head and neck carcinoma patients [2].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ASXL1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ATM is altered in 4.14% of head and neck carcinoma patients [2].

ATM is an inclusion eligibility criterion in 4 clinical trials for head and neck carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ATM status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].

ATR is altered in 4.08% of head and neck carcinoma patients [2].

ATR is an inclusion eligibility criterion in 4 clinical trials for head and neck carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ATR status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].

BARD1 is altered in 1.37% of head and neck carcinoma patients [2].

BARD1 is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BARD1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

BLM is altered in 1.96% of head and neck carcinoma patients [2].

BLM is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BLM status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

BRAF is altered in 1.6% of head and neck carcinoma patients [2].

BRAF is an inclusion eligibility criterion in 3 clinical trials for head and neck carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRAF status and head and neck carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [3].

BRCA1 is altered in 3.05% of head and neck carcinoma patients [2].

BRCA1 is an inclusion eligibility criterion in 5 clinical trials for head and neck carcinoma, of which 4 are open and 1 is closed. Of the trials that contain BRCA1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

BRCA2 is altered in 4.85% of head and neck carcinoma patients [2].

BRCA2 is an inclusion eligibility criterion in 5 clinical trials for head and neck carcinoma, of which 4 are open and 1 is closed. Of the trials that contain BRCA2 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

BRIP1 is altered in 1.82% of head and neck carcinoma patients [2].

BRIP1 is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRIP1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

BTRC is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BTRC status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CCND1 is altered in 7.83% of head and neck carcinoma patients [2].

CCND1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK12 is altered in 3.15% of head and neck carcinoma patients [2].

CDK12 is an inclusion eligibility criterion in 4 clinical trials for head and neck carcinoma, of which 3 are open and 1 is closed. Of the trials that contain CDK12 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].

CDK4 is altered in 1.03% of head and neck carcinoma patients [2].

CDK4 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK6 is altered in 1.42% of head and neck carcinoma patients [2].

CDK6 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDKN1A is altered in 0.67% of head and neck carcinoma patients [2].

CDKN1A is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1A status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CDKN1B is altered in 0.98% of head and neck carcinoma patients [2].

CDKN1B is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1B status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CDKN2A is altered in 17.99% of head and neck carcinoma patients [2].

CDKN2A is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CDKN2A status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

CHD4 is altered in 4.17% of head and neck carcinoma patients [2].

CHD4 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CHD4 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CHEK1 is altered in 0.59% of head and neck carcinoma patients [2].

CHEK1 is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CHEK1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

CHEK2 is altered in 1.61% of head and neck carcinoma patients [2].

CHEK2 is an inclusion eligibility criterion in 3 clinical trials for head and neck carcinoma, of which 3 are open and 0 are closed. Of the trials that contain CHEK2 status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

CSF1R is altered in 1.18% of head and neck carcinoma patients [2].

CSF1R is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CYLD is altered in 6.03% of head and neck carcinoma patients [2].

CYLD is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CYLD status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

DICER1 is altered in 1.48% of head and neck carcinoma patients [2].

DICER1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains DICER1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

DNMT3A is altered in 1.89% of head and neck carcinoma patients [2].

DNMT3A is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains DNMT3A status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

DVL1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DVL1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

EGFR is altered in 4.29% of head and neck carcinoma patients [2].

EGFR is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

EPCAM is altered in 0.44% of head and neck carcinoma patients [2].

EPCAM is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 is altered in 4.04% of head and neck carcinoma patients [2].

ERBB2 is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

ERBB3 is altered in 2.81% of head and neck carcinoma patients [2].

ERBB3 is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERBB3 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

EXO1 is altered in 1.17% of head and neck carcinoma patients [2].

EXO1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EXO1 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EZH2 is altered in 1.19% of head and neck carcinoma patients [2].

EZH2 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

FANCA is altered in 2.58% of head and neck carcinoma patients [2].

FANCA is an inclusion eligibility criterion in 3 clinical trials for head and neck carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FANCA status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

FANCB is altered in 1.83% of head and neck carcinoma patients [2].

FANCB is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FANCB status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FANCC is altered in 0.7% of head and neck carcinoma patients [2].

FANCC is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FANCC status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FANCD2 is altered in 2.66% of head and neck carcinoma patients [2].

FANCD2 is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FANCD2 status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FANCE is altered in 1.03% of head and neck carcinoma patients [2].

FANCE is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FANCE status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FANCF is altered in 0.8% of head and neck carcinoma patients [2].

FANCF is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FANCF status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FANCG is altered in 0.8% of head and neck carcinoma patients [2].

FANCG is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FANCG status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FANCI is altered in 2.56% of head and neck carcinoma patients [2].

FANCI is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FANCI status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FANCL is altered in 1.98% of head and neck carcinoma patients [2].

FANCL is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FANCL status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FANCM is altered in 5.5% of head and neck carcinoma patients [2].

FANCM is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FANCM status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FGFR1 is altered in 1.96% of head and neck carcinoma patients [2].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR2 is altered in 1.56% of head and neck carcinoma patients [2].

FGFR2 is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

FGFR3 is altered in 2.33% of head and neck carcinoma patients [2].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT1 is altered in 2.25% of head and neck carcinoma patients [2].

FLT1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 is altered in 1.34% of head and neck carcinoma patients [2].

FLT3 is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FLT3 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

FLT4 is altered in 2.68% of head and neck carcinoma patients [2].

FLT4 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FZD1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD10 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD2 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD2 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD3 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD3 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD4 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD4 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD5 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD5 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD6 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD6 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD7 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD7 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD8 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD8 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD9 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD9 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

GATA3 is altered in 1.08% of head and neck carcinoma patients [2].

GATA3 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

HGF is altered in 2.13% of head and neck carcinoma patients [2].

HGF is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HGF status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

IDH1 is altered in 0.52% of head and neck carcinoma patients [2].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KDM6A is altered in 5.08% of head and neck carcinoma patients [2].

KDM6A is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KDR is altered in 2.69% of head and neck carcinoma patients [2].

KDR is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KDR status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

KEAP1 is altered in 2.37% of head and neck carcinoma patients [2].

KEAP1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KEAP1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KIT is altered in 2.11% of head and neck carcinoma patients [2].

KIT is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

KMT2D is altered in 15.25% of head and neck carcinoma patients [2].

KMT2D is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KRAS is altered in 2.14% of head and neck carcinoma patients [2].

KRAS is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KRAS status and head and neck carcinoma as inclusion criteria, 2 are phase 1 (1 open) [3].

LRP5 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains LRP5 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

LRP6 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains LRP6 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAGI2 is altered in 0.56% of head and neck carcinoma patients [2].

MAGI2 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MAGI2 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MAP3K1 is altered in 1.69% of head and neck carcinoma patients [2].

MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MAP3K1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MCPH1 is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MCPH1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MED12 is altered in 3.05% of head and neck carcinoma patients [2].

MED12 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MET is altered in 2.08% of head and neck carcinoma patients [2].

MET is an inclusion eligibility criterion in 3 clinical trials for head and neck carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MET status and head and neck carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MLH1 is altered in 1.3% of head and neck carcinoma patients [2].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLH3 is altered in 2.91% of head and neck carcinoma patients [2].

MLH3 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH3 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MRE11A is altered in 1.04% of head and neck carcinoma patients [2].

MRE11A is an inclusion eligibility criterion in 3 clinical trials for head and neck carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MRE11A status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

MSH2 is altered in 1.49% of head and neck carcinoma patients [2].

MSH2 is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MSH2 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

MSH3 is altered in 1.36% of head and neck carcinoma patients [2].

MSH3 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH6 is altered in 1.94% of head and neck carcinoma patients [2].

MSH6 is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MSH6 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

MST1R is altered in 1.42% of head and neck carcinoma patients [2].

MST1R is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MST1R status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MTOR is altered in 2.88% of head and neck carcinoma patients [2].

MTOR is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MYC is altered in 2.64% of head and neck carcinoma patients [2].

MYC is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NBN is altered in 1.39% of head and neck carcinoma patients [2].

NBN is an inclusion eligibility criterion in 3 clinical trials for head and neck carcinoma, of which 3 are open and 0 are closed. Of the trials that contain NBN status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

NF1 is altered in 4.2% of head and neck carcinoma patients [2].

NF1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NF1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NF2 is altered in 1.17% of head and neck carcinoma patients [2].

NF2 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NOTCH1 is altered in 13.39% of head and neck carcinoma patients [2].

NOTCH1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NOTCH2 is altered in 5.01% of head and neck carcinoma patients [2].

NOTCH2 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH2 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NRAS is altered in 1.08% of head and neck carcinoma patients [2].

NRAS is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NRG1 is altered in 0.51% of head and neck carcinoma patients [2].

NRG1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRG1 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NSD1 is altered in 4.81% of head and neck carcinoma patients [2].

NSD1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NSD1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NTRK1 is altered in 2.42% of head and neck carcinoma patients [2].

NTRK1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK2 is altered in 1.46% of head and neck carcinoma patients [2].

NTRK2 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK3 is altered in 3.26% of head and neck carcinoma patients [2].

NTRK3 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PALB2 is altered in 1.51% of head and neck carcinoma patients [2].

PALB2 is an inclusion eligibility criterion in 3 clinical trials for head and neck carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PALB2 status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

PCNA is altered in 2.63% of head and neck carcinoma patients [2].

PCNA is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PCNA status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA is altered in 2.14% of head and neck carcinoma patients [2].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRB is altered in 1.55% of head and neck carcinoma patients [2].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PIK3C2B is altered in 3.21% of head and neck carcinoma patients [2].

PIK3C2B is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3C2B status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PIK3CA is altered in 16.17% of head and neck carcinoma patients [2].

PIK3CA is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PIK3CA status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

PIK3CB is altered in 1.89% of head and neck carcinoma patients [2].

PIK3CB is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3CB status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PIK3R1 is altered in 2.26% of head and neck carcinoma patients [2].

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3R1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PMS1 is altered in 1.37% of head and neck carcinoma patients [2].

PMS1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS1 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PMS2 is altered in 1.57% of head and neck carcinoma patients [2].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

POLD1 is altered in 1.55% of head and neck carcinoma patients [2].

POLD1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLD1 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

POLE is altered in 2.72% of head and neck carcinoma patients [2].

POLE is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain POLE status and head and neck carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

PTCH1 is altered in 2.62% of head and neck carcinoma patients [2].

PTCH1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PTCH1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PTEN is altered in 5.25% of head and neck carcinoma patients [2].

PTEN is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

PTPN11 is altered in 0.75% of head and neck carcinoma patients [2].

PTPN11 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PTPN11 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

RAD50 is altered in 1.17% of head and neck carcinoma patients [2].

RAD50 is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD50 status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RAD51 is altered in 0.36% of head and neck carcinoma patients [2].

RAD51 is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51 status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RAD51B is altered in 0.3% of head and neck carcinoma patients [2].

RAD51B is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51B status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RAD51C is altered in 1.27% of head and neck carcinoma patients [2].

RAD51C is an inclusion eligibility criterion in 3 clinical trials for head and neck carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RAD51C status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

RAD51D is altered in 0.6% of head and neck carcinoma patients [2].

RAD51D is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51D status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RAD54L is altered in 0.35% of head and neck carcinoma patients [2].

RAD54L is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD54L status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RAF1 is altered in 1.03% of head and neck carcinoma patients [2].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RB1 is altered in 4.03% of head and neck carcinoma patients [2].

RB1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

RET is altered in 1.93% of head and neck carcinoma patients [2].

RET is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RET status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

RFC1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC1 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC2 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC2 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC3 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC3 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC4 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC4 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC5 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC5 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RNF43 is altered in 1.64% of head and neck carcinoma patients [2].

RNF43 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RNF43 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ROS1 is altered in 3.54% of head and neck carcinoma patients [2].

ROS1 is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ROS1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

RPA1 is altered in 0.78% of head and neck carcinoma patients [2].

RPA1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA1 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA2 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA3 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA3 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA4 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA4 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RSPO1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RSPO1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RUNX1 is altered in 1.67% of head and neck carcinoma patients [2].

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SETD2 is altered in 3.72% of head and neck carcinoma patients [2].

SETD2 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SETD2 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SLX4 is altered in 2.68% of head and neck carcinoma patients [2].

SLX4 is an inclusion eligibility criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain SLX4 status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

SMARCA4 is altered in 3.85% of head and neck carcinoma patients [2].

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SOX9 is altered in 1.34% of head and neck carcinoma patients [2].

SOX9 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SOX9 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SSBP1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SSBP1 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

STAG2 is altered in 1.53% of head and neck carcinoma patients [2].

STAG2 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains STAG2 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TAF1 is altered in 1.2% of head and neck carcinoma patients [2].

TAF1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TAF1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TBX3 is altered in 1.49% of head and neck carcinoma patients [2].

TBX3 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TBX3 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TET2 is altered in 3.46% of head and neck carcinoma patients [2].

TET2 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TET2 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TP53 is altered in 37.19% of head and neck carcinoma patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TSC1 is altered in 1.56% of head and neck carcinoma patients [2].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TSC2 is altered in 2.69% of head and neck carcinoma patients [2].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VHL is altered in 0.29% of head and neck carcinoma patients [2].

VHL is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

WNT1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains WNT1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

XPO1 is altered in 0.87% of head and neck carcinoma patients [2].

XPO1 is an inclusion eligibility criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains XPO1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [3].